These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 17264759

  • 1. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC, Bernard JL.
    Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
    [Abstract] [Full Text] [Related]

  • 2. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.
    Clin Ther; 2009 Mar; 31 Pt 2():2388-95. PubMed ID: 20110048
    [Abstract] [Full Text] [Related]

  • 3. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
    Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G.
    Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pegfilgrastim use during chemotherapy: current and future applications.
    Wolf T, Densmore JJ.
    Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS.
    Cancer; 2009 Oct 15; 115(20):4839-48. PubMed ID: 19637341
    [Abstract] [Full Text] [Related]

  • 10. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR.
    Eur J Cancer Care (Engl); 2004 Sep 15; 13(4):371-9. PubMed ID: 15305906
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G.
    Oncology; 2009 Sep 15; 77(2):107-12. PubMed ID: 19622901
    [Abstract] [Full Text] [Related]

  • 13. Pegfilgrastim for chemotherapy-induced neutropenia.
    Bedell C.
    Clin J Oncol Nurs; 2003 Sep 15; 7(1):55-6, 63-4. PubMed ID: 12629935
    [Abstract] [Full Text] [Related]

  • 14. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G.
    Exp Hematol; 2006 Oct 15; 34(10):1296-302. PubMed ID: 16982322
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N, Sekine I, Nakagawa K, Takada M, Fukuoka M, Tanigawara Y, Saijo N.
    Jpn J Clin Oncol; 2009 Jul 15; 39(7):425-30. PubMed ID: 19395467
    [Abstract] [Full Text] [Related]

  • 18. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
    Schuman SI, Lambrou N, Robson K, Glück S, Myriounis N, Pearson JM, Lucci JA.
    J Support Oncol; 2009 Jul 15; 7(6):225-8. PubMed ID: 20380330
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
    Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M.
    Eur J Cancer; 2006 Nov 15; 42(17):2976-81. PubMed ID: 17008093
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH, Lalla A, Barron RL, Dubois RW.
    Clin Ther; 2009 May 15; 31(5):1092-104. PubMed ID: 19539110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.